4,537 Shares in PTC Therapeutics, Inc. $PTCT Bought by CFC Planning Co LLC

CFC Planning Co LLC bought a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,537 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

Other hedge funds also recently added to or reduced their stakes in the company. AlphaQuest LLC increased its holdings in shares of PTC Therapeutics by 337.7% in the 2nd quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after acquiring an additional 6,102 shares during the period. Sector Gamma AS grew its position in PTC Therapeutics by 41.4% in the 1st quarter. Sector Gamma AS now owns 92,250 shares of the biopharmaceutical company’s stock worth $4,701,000 after purchasing an additional 27,000 shares during the last quarter. Deutsche Bank AG grew its position in PTC Therapeutics by 262.1% in the 1st quarter. Deutsche Bank AG now owns 341,724 shares of the biopharmaceutical company’s stock worth $17,414,000 after purchasing an additional 247,346 shares during the last quarter. Cerity Partners LLC acquired a new stake in shares of PTC Therapeutics in the first quarter valued at approximately $641,000. Finally, Nuveen LLC acquired a new stake in shares of PTC Therapeutics in the first quarter valued at approximately $51,427,000.

PTC Therapeutics Trading Up 1.1%

NASDAQ:PTCT opened at $76.46 on Friday. PTC Therapeutics, Inc. has a twelve month low of $35.95 and a twelve month high of $78.74. The company has a 50-day moving average of $66.68 and a 200-day moving average of $55.20. The firm has a market cap of $6.14 billion, a price-to-earnings ratio of 10.97 and a beta of 0.60.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The business had revenue of $211.01 million for the quarter, compared to the consensus estimate of $177.42 million. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.39) EPS. PTC Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Neil Gregory Almstead sold 55,000 shares of the firm’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $66.05, for a total transaction of $3,632,750.00. Following the completion of the sale, the insider directly owned 100,625 shares of the company’s stock, valued at $6,646,281.25. This trade represents a 35.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Mark Elliott Boulding sold 2,812 shares of PTC Therapeutics stock in a transaction on Monday, November 17th. The stock was sold at an average price of $75.99, for a total value of $213,683.88. Following the completion of the transaction, the vice president owned 103,901 shares in the company, valued at $7,895,436.99. The trade was a 2.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 264,807 shares of company stock worth $16,760,813 over the last quarter. 5.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on PTCT shares. Morgan Stanley decreased their price objective on PTC Therapeutics from $76.00 to $71.00 and set an “overweight” rating for the company in a report on Wednesday, August 20th. The Goldman Sachs Group increased their target price on shares of PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a research report on Wednesday, November 5th. Wells Fargo & Company boosted their price target on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a report on Wednesday. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $75.40.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.